- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Secukinumab 300 mg, Placebo
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–29
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- secukinumab 150 mg, secukinumab 300 mg, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more
- Conditions
- Chronic Plaque Psoriasis, Psoriasis
- Interventions
- M923, Humira
- Biological
- Lead sponsor
- Momenta Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 24
- States / cities
- Beverly Hills, California • Encino, California • La Mesa, California + 20 more
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- Secukinumab (AIN457), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- AIN457 150mg, AIN457 300mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 967 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 33
- States / cities
- Fresno, California • Pasadena, California • Sacramento, California + 28 more